Charlson Comorbidity Index (CCI)
Very recent study found significant improvement of behavioral deficits including cognitive decline, depressive-like behaviors, in APP (NLG-F/NLG-FG-) mice due to oral GSH administration
Data requests, including individual anonymized participant data, will be considered for sharing (1) once the product and indication has been approved by major health authorities (e.g., FDA, EMA, PMDA, etc.) or development of the product has been discontinued globally for all indications on or after April 2020 and there are no plans for future development, (2) if there is legal authority to share the data, and (3) there is not a reasonable likelihood of participant re-identification
If 2 or more consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate Wegovy and follow the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment